Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2022 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Annual Cowen Health Care Conference

ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 28, 2022 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results

Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early...
February 22, 2022 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 22, 2022 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
December 08, 2021 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 24, 2021 18:58 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Targeted in Ransomware Incident

The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations No ransom payments have been made by the Company ROCKVILLE, Md., Nov. 24,...
November 24, 2021 09:12 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas...
November 23, 2021 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements...
November 18, 2021 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Annual Piper Sandler Healthcare Conference

ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 10, 2021 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Upcoming November Investor Conferences

ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...